MX2022007371A - Tratamiento del hipoparatiroidismo. - Google Patents
Tratamiento del hipoparatiroidismo.Info
- Publication number
- MX2022007371A MX2022007371A MX2022007371A MX2022007371A MX2022007371A MX 2022007371 A MX2022007371 A MX 2022007371A MX 2022007371 A MX2022007371 A MX 2022007371A MX 2022007371 A MX2022007371 A MX 2022007371A MX 2022007371 A MX2022007371 A MX 2022007371A
- Authority
- MX
- Mexico
- Prior art keywords
- treatment
- hypoparathyroidism
- pth compound
- patient
- titrating
- Prior art date
Links
- 208000000038 Hypoparathyroidism Diseases 0.000 title abstract 2
- 150000001875 compounds Chemical class 0.000 abstract 3
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/34—Macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyesters, polyamino acids, polysiloxanes, polyphosphazines, copolymers of polyalkylene glycol or poloxamers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/22—Hormones
- A61K38/29—Parathyroid hormone, i.e. parathormone; Parathyroid hormone-related peptides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/22—Heterocyclic compounds, e.g. ascorbic acid, tocopherol or pyrrolidones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
- A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
- A61K47/60—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/18—Drugs for disorders of the endocrine system of the parathyroid hormones
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Endocrinology (AREA)
- Epidemiology (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Diabetes (AREA)
- Zoology (AREA)
- Immunology (AREA)
- Gastroenterology & Hepatology (AREA)
- Inorganic Chemistry (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Peptides Or Proteins (AREA)
- Steroid Compounds (AREA)
- Medicinal Preparation (AREA)
Abstract
La presente invención se relaciona con un compuesto de PTH para usarse en el tratamiento de hipoparatiroidismo, en donde el tratamiento comprende administraciones diarias únicas del compuesto de PTH a un paciente y ajuste de la dosis del paciente fuera de la norma de cuidado dentro de las cuatro semanas a partir del momento en que se administró la primera dosis del compuesto de PTH.
Applications Claiming Priority (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP20151350 | 2020-01-13 | ||
EP20192565 | 2020-08-25 | ||
EP20216065 | 2020-12-21 | ||
PCT/EP2021/050460 WO2021144249A1 (en) | 2020-01-13 | 2021-01-12 | Hypoparathyroidism treatment |
Publications (1)
Publication Number | Publication Date |
---|---|
MX2022007371A true MX2022007371A (es) | 2022-07-12 |
Family
ID=74187267
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
MX2022007371A MX2022007371A (es) | 2020-01-13 | 2021-01-12 | Tratamiento del hipoparatiroidismo. |
Country Status (11)
Country | Link |
---|---|
US (1) | US20230042670A1 (es) |
EP (1) | EP4090357A1 (es) |
JP (1) | JP2023510790A (es) |
KR (1) | KR20220128390A (es) |
CN (1) | CN115003320A (es) |
AU (1) | AU2021208398A1 (es) |
BR (1) | BR112022010419A2 (es) |
CA (1) | CA3161101A1 (es) |
IL (1) | IL294357A (es) |
MX (1) | MX2022007371A (es) |
WO (1) | WO2021144249A1 (es) |
Families Citing this family (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
MX2018009938A (es) | 2016-03-01 | 2019-03-14 | Ascendis Pharma Bone Diseases As | Profarmacos de hormona paratiroidea (pth). |
BR112019005793A2 (pt) | 2016-09-29 | 2019-06-18 | Ascendis Pharma Bone Diseases As | compostos de pth com baixas proporções de pico-para-vale |
SI3518960T1 (sl) | 2016-09-29 | 2023-11-30 | Ascendis Pharma Bone Diseases A/S, | Odmerni režim za PTH spojino z nadzorovanim sproščanjem |
AU2022350937A1 (en) * | 2021-09-22 | 2024-03-21 | Ascendis Pharma Bone Diseases A/S | Long-acting pth compound treatments |
WO2024094673A1 (en) * | 2022-11-02 | 2024-05-10 | Ascendis Pharma Bone Diseases A/S | Pth treatment regimen comprising two pth compounds |
Family Cites Families (37)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6624142B2 (en) | 1997-12-30 | 2003-09-23 | Enzon, Inc. | Trimethyl lock based tetrapartate prodrugs |
US7332164B2 (en) | 2003-03-21 | 2008-02-19 | Enzon Pharmaceuticals, Inc. | Heterobifunctional polymeric bioconjugates |
WO2004089280A2 (en) | 2003-04-08 | 2004-10-21 | Yeda Research And Development Co. Ltd. | Reversible pegylated drugs |
US7690003B2 (en) | 2003-08-29 | 2010-03-30 | Fuller Jeffrey C | System and method for increasing data throughput using thread scheduling |
US20070203058A1 (en) | 2003-09-19 | 2007-08-30 | Novo Nordisk A/S | Novel Glp-1 Derivatives |
AU2005232371B2 (en) | 2004-03-23 | 2010-10-14 | Complex Biosystems Gmbh | Polymeric prodrug with a self-immolative linker |
GB2427360A (en) | 2005-06-22 | 2006-12-27 | Complex Biosystems Gmbh | Aliphatic prodrug linker |
US8450269B2 (en) | 2006-02-03 | 2013-05-28 | Prolor Biotech Ltd. | Long-acting growth hormone and methods of producing same |
MX2009002859A (es) | 2006-09-15 | 2009-03-30 | Enzon Pharmaceuticals Inc | Enlazadores biodegradables a base de ester impedido para suministro de oligonucleotidos. |
DE602008005596D1 (de) | 2007-06-21 | 2011-04-28 | Univ Muenchen Tech | Biologisch aktive proteine mit erhöhter in-vivo- und/oder in-vitro-stabilität |
US20090016985A1 (en) | 2007-07-11 | 2009-01-15 | Enzon Pharmaceuticals, Inc. | Polymeric drug delivery system containing a multi-substituted aromatic moiety |
PT2237799T (pt) | 2008-02-01 | 2019-07-05 | Ascendis Pharma As | Pró-fármaco compreendendo um ligador autoclivável |
US20110105413A1 (en) | 2008-05-23 | 2011-05-05 | Enzon Pharmaceuticals, Inc. | Polymeric systems containing intracellular releasable disulfide linker for the delivery of oligonucleotides |
EP2459227B1 (en) | 2009-07-31 | 2021-03-17 | Ascendis Pharma A/S | Prodrugs containing an aromatic amine connected by an amide bond to a carrier |
EP2519228A4 (en) | 2009-12-31 | 2013-06-19 | Enzon Pharmaceuticals Inc | POLYMER CONJUGATES FROM AN AROMATIC AMINE WITH COMPOUNDS WITH A CLEANER UREA CONTAINER |
EP2525831B1 (en) | 2010-01-22 | 2019-05-15 | Ascendis Pharma A/S | Carrier-linked carbamate prodrug linkers |
WO2011089215A1 (en) | 2010-01-22 | 2011-07-28 | Ascendis Pharma As | Dipeptide-based prodrug linkers for aromatic amine-containing drugs |
EP2525830B1 (en) | 2010-01-22 | 2016-05-11 | Ascendis Pharma A/S | Dipeptide-based prodrug linkers for aliphatic amine-containing drugs |
EP2552967A4 (en) | 2010-04-02 | 2014-10-08 | Amunix Operating Inc | BINDING FUSION PROTEINS, BINDING FUSION PROTEIN MEDICINAL CONJUGATES, XTEN MEDICAMENT CONJUGATES, AND METHOD FOR THEIR PREPARATION AND USE |
JP5977229B2 (ja) | 2010-05-05 | 2016-08-24 | プロリンクス リミテッド ライアビリティ カンパニー | 巨大分子共役体からの徐放 |
DK2566334T3 (en) | 2010-05-05 | 2018-07-23 | Prolynx Llc | MANAGED PHARMACEUTICAL RELEASE FROM SOLID CARRIERS |
WO2011143406A2 (en) * | 2010-05-13 | 2011-11-17 | The General Hospital Corporation | Parathyroid hormone analogs and uses thereof |
EP3473261A1 (en) | 2010-05-21 | 2019-04-24 | XL-protein GmbH | Biosynthetic proline/alanine random coil polypeptides and their uses |
US8989456B2 (en) | 2010-06-30 | 2015-03-24 | Nec Solution Innovators, Ltd. | Attribute determining method, attribute determining apparatus, program, recording medium, and attribute determining system |
AU2012296950B2 (en) | 2011-08-12 | 2016-09-22 | Ascendis Pharma A/S | Polymeric hyperbranched carrier-linked prodrugs |
EP3643306A3 (en) | 2011-08-12 | 2020-08-26 | Ascendis Pharma A/S | Carrier-linked prodrugs having reversible carboxylic ester linkages |
US9561287B2 (en) | 2011-08-12 | 2017-02-07 | Ascendis Pharma A/S | Carrier-linked treprostinil prodrugs |
US20140323402A1 (en) | 2011-08-12 | 2014-10-30 | Ascendis Phama A/S | Protein Carrier-Linked Prodrugs |
WO2013036857A1 (en) | 2011-09-07 | 2013-03-14 | Prolynx Llc | Sulfone linkers |
CA2868925C (en) | 2012-04-25 | 2020-01-21 | Ascendis Pharma A/S | Prodrugs of hydroxyl-comprising drugs |
EP2908845A1 (en) | 2012-10-17 | 2015-08-26 | Novo Nordisk Health Care AG | Fatty acid acylated amino acids for growth hormone delivery |
US20200354428A9 (en) * | 2013-06-23 | 2020-11-12 | Wisconsin Alumni Research Foundation | Analogues of parathyroid hormone (1-34) that function as agonists of the parathyroid hormone receptor-1 and display modified activity profiles |
US11633487B2 (en) | 2014-08-06 | 2023-04-25 | Ascendis Pharma A/S | Prodrugs comprising an aminoalkyl glycine linker |
BR112019005793A2 (pt) | 2016-09-29 | 2019-06-18 | Ascendis Pharma Bone Diseases As | compostos de pth com baixas proporções de pico-para-vale |
US20190224329A1 (en) * | 2016-09-29 | 2019-07-25 | Ascendis Pharma Bone Diseases A/S | Incremental Dose Finding in Controlled-Release PTH Compounds |
WO2019219896A1 (en) * | 2018-05-18 | 2019-11-21 | Ascendis Pharma Bone Diseases A/S | Starting dose of pth conjugates |
AU2020253560A1 (en) | 2019-04-05 | 2021-11-25 | Prolynx Llc | Improved conjugation linkers |
-
2021
- 2021-01-12 MX MX2022007371A patent/MX2022007371A/es unknown
- 2021-01-12 EP EP21700696.4A patent/EP4090357A1/en active Pending
- 2021-01-12 WO PCT/EP2021/050460 patent/WO2021144249A1/en unknown
- 2021-01-12 KR KR1020227027792A patent/KR20220128390A/ko unknown
- 2021-01-12 IL IL294357A patent/IL294357A/en unknown
- 2021-01-12 US US17/783,640 patent/US20230042670A1/en active Pending
- 2021-01-12 CN CN202180009185.0A patent/CN115003320A/zh active Pending
- 2021-01-12 CA CA3161101A patent/CA3161101A1/en active Pending
- 2021-01-12 JP JP2022542344A patent/JP2023510790A/ja active Pending
- 2021-01-12 BR BR112022010419A patent/BR112022010419A2/pt unknown
- 2021-01-12 AU AU2021208398A patent/AU2021208398A1/en active Pending
Also Published As
Publication number | Publication date |
---|---|
KR20220128390A (ko) | 2022-09-20 |
AU2021208398A1 (en) | 2022-06-09 |
CN115003320A (zh) | 2022-09-02 |
JP2023510790A (ja) | 2023-03-15 |
IL294357A (en) | 2022-08-01 |
BR112022010419A2 (pt) | 2022-08-23 |
CA3161101A1 (en) | 2021-07-22 |
WO2021144249A1 (en) | 2021-07-22 |
EP4090357A1 (en) | 2022-11-23 |
US20230042670A1 (en) | 2023-02-09 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
MX2022007371A (es) | Tratamiento del hipoparatiroidismo. | |
RU2356547C2 (ru) | Способы лечения рака с использованием ингибиторов hdac | |
EP4272818A3 (en) | Thrombolytic agent for the treatment of thromboembolism | |
WO2019199861A3 (en) | Hemp extract for treatment of pain in animals | |
MX2022003072A (es) | Uso de pridopidina para el tratamiento de la disminucion funcional. | |
AU2016354007A8 (en) | Therapeutic compositions for treatment of human immunodeficiency virus | |
MX2020014000A (es) | Formulaciones en lámina que contienen dexmedetomidina y métodos para producirlas. | |
ECSP045029A (es) | Composiciones de valdecoxib de disgregación intraoral | |
MX2023000187A (es) | Dosificacion de vibegron para el tratamiento de vejiga sobreactiva. | |
AU2018282104A1 (en) | Use of vibegron to treat overactive bladder | |
RU2017120184A (ru) | Лекарства для замедления течения болезни паркинсона | |
SI1594885T1 (sl) | Zdravilo za inhibiranje rasti tumorjev | |
NZ751972A (en) | Treatment of prurigo nodularis | |
MX2015009546A (es) | Dosificacion aumentada de efavirenz para el tratamiento de cancer. | |
MX2013003523A (es) | Composicion farmaceutica de dosis baja. | |
ZA201905212B (en) | Rescue treatment of post operative nausea and vomiting | |
AR039895A1 (es) | Composicion que comprende una vitamina, una sal de metal y una insulina o una hormona del crecimiento y uso de dichos componentes para prepararla | |
MX2021000714A (es) | Preparacion medicinal para uso externo. | |
GEP20227384B (en) | Topical formulations comprising strontium and methylsulfonylmethane (msm) and methods of treatment | |
HUP0401634A2 (hu) | LHRH-antagonisták használata kasztrációt nem okozó dózisokban a T-sejtes immunitás javítására és gyógyszerkészítmények előállítására | |
MX2012005497A (es) | Tivozanib y temsirolimus en combinacion. | |
JOP20170044B1 (ar) | تركيبة صيدلانية تشتمل على hgh ناتج عن عودة الارتباط الجيني لعلاج نقص هرمون النمو | |
CA3199014A1 (en) | Combination therapy for the treatment of a liver disease | |
MX2021004138A (es) | Metodos y formulaciones para tratar nauseas y vomito inducidos por quimioterapias. | |
RU2020108631A (ru) | Новая вспомогательная терапия для применения в способе лечения рака простаты |